logo
"Forever chemicals" found in fish caught in San Francisco Bay, report warns

"Forever chemicals" found in fish caught in San Francisco Bay, report warns

CBS News11-06-2025

A warning to anglers who eat their catch from the San Francisco Bay, fish pulled from the waters may contain dangerous levels of so-called "forever chemicals."
In a recent report by the San Francisco Estuary Institute, scientists detected 20 types of polyfluoroalkyl substances, known as PFAS in fish caught in the bay.
Their research and testing of fish began in 2009, and a revised study was published in the American Chemical Society this past March.
"PFAS have been known to harm us in a variety of different ways, they've been known to cause cancer," said Miguel Mendez, the lead author of the SFEI study. "It affects us in variety of different organs, including the liver, and over time can cause some severe health effects."
Along the docks of San Francisco's Embarcadero, one will find a variety of fisherman who are there for sport or relaxation, but a number of people fish the docks for food.
"I think for communities, especially those that are eating every day from the Bay, that is a huge concern and likely leading to a higher load of PFAS and other contaminants, for these populations," said Mendez.
Along Pier One, longtime anglers Danny Tran and Nick Hayden were posted up on a sunny afternoon, and both say while they love to fish, they are careful about how much of their catch they consume.
"I don't eat too much fish, so I'm okay with it," said Tran. "I probably eat once a month, twice a month and that's about it."
"You have to choose what you eat, the smaller (younger) the better, because there's less chemicals in them," said Hayden. "The bigger ones have higher levels of mercury, or whatever they have inside of them."
Currently there are no specific state guidelines on the consumption of fish in relation to PFAS. But since 2011 the California Office of Environmental Health Hazard Assessments has offered recommendations on 18 fish species on which types of fish to avoid, which fish are safe to eat, and how many servings are recommended per week, along with gender and age advisories.
They updated their recommendations in April of 2023, and have posted signs along local docks.
Where anglers catch their fish, can also determine the level of "forever chemicals." SFEI conducted tests in 12 different locations and found higher levels of PFAS in the South Bay.
"The South Bay is a hotspot for PFAS, but that doesn't mean that the North Bay is the immune or doesn't have PFAS at all, because fish can swim for location to location," said Mendez. "To those who may have a seafood heavy diet, you should really think about where is my seafood coming from."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This week on "Sunday Morning" (June 29)
This week on "Sunday Morning" (June 29)

Yahoo

time22 minutes ago

  • Yahoo

This week on "Sunday Morning" (June 29)

The Emmy Award-winning "CBS News Sunday Morning" is broadcast on CBS Sundays beginning at 9:00 a.m. ET. "Sunday Morning" also streams on the CBS News app beginning at 11:00 a.m. ET. (Download it here.) Guest host: Lee Cowan COVER STORY: "When is cancer political?" Medical researchers, patients decry Trump admin's layoffs, budget cutsScientists conducting medical research are facing an existential crisis: Layoffs and budget cuts pushed by President Trump that, they say, jeopardize finding a cure for cancer. They tell "Sunday Morning" senior contributor Ted Koppel that what was once an issue receiving strong bipartisan support – cancer research – is now falling under the administration's budget axe. Koppel also talks with cancer patients taking part in clinical trials for treatments and vaccines, whose own contributions to finding a cure are imperiled. For more info: National Cancer InstituteNational Institutes of HealthSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, BaltimoreAmerican Association for Cancer Research ALMANAC: June 29"Sunday Morning" looks back at historical events on this date. WORLD: Scanning the heavens at the Vatican ObservatoryPerched in the hills outside Rome sits the Palace of Castel Gandolfo, the centuries-old lakeside summer home for popes, which is also home to the Vatican Observatory, established in 1891 to help bridge the chasm between religion and science. Correspondent Seth Doane talks with scientists and students for whom the Church's observations of the heavens are a means to unite people beyond faith. For more info: Vatican ObservatoryCastel Gandolfo (Vatican Museums)The Galileo Museum, Florence, ItalyVera C. Rubin Observatory, Chile BUSINESS: Uber CEO Dara Khosrowshahi on being behind the wheelHe's the son of an immigrant family who fled Tehran and the Iranian revolution. He's also the chief executive officer of Uber, who has worked to change the culture of the company he took over in 2017, helping make it a leading transportation platform. CEO Dara Khosrowshahi talks with correspondent Jo Ling Kent about the road to high-tech success, and about unsettling times for a nation of immigrants. For more info: UberUber EatsWaymo HARTMAN: Birds PASSAGE: In memoriam"Sunday Morning" remembers some of the notable figures who left us this week. MUSIC: Conductor Michael Tilson Thomas on leaving the podiumFor more than half a century, conductor-composer Michael Tilson Thomas has graced the stages of concert halls with a swashbuckling style. Earlier this year, Thomas led the San Francisco Symphony in his last scheduled conducting performance due to the return of his glioblastoma – an aggressive brain tumor. He talks with "60 Minutes" correspondent Lesley Stahl about how he was changed by conducting for the first time in junior high school, and about living a life in the arts. You can stream the album "Grace: The Music of Michael Tilson Thomas" by clicking on the embed below (Free Spotify registration required to hear the tracks in full): For more info: Michael Tilson ThomasSan Francisco SymphonyNew World Symphony, Miami COMMENTARY: Jim Gaffigan on fireworks For more info: MOVIES: Look, up in the sky! A new "Superman" arrivesSuperman, created by Jerry Siegel and Joe Shuster, has been flying in comic books, radio, TV and movies for almost 90 years. And now, D.C. Studios is bringing him back to the big screen in the new movie, "Superman." Turner Classic Movies host Ben Mankiewicz talks with director James Gunn about his re-imagining of the Man of Steel, and with actor David Corenswet about the challenges of taking on the role following Christopher Reeve's preeminent performance. Mankiewicz also talks with critic Elvis Mitchell about how – in an era of superhero movies – Superman is unique. To watch a trailer for "Superman," click on the video player below: For more info: "Superman" opens in theaters and in Imax July 11Thanks to the Arden Theatre Company, Philadelphia BOOKS: William Buckley and his drive to push America to the rightWilliam F. Buckley, Jr. was a leading commentator who had a vital role in elevating Joseph McCarthy, Barry Goldwater and Ronald Reagan, catalyzing a conservative movement that reshaped the Republican Party – and the country. "Sunday Morning" national correspondent Robert Costa talks with Sam Tanenhaus (author of the new biography, "Buckley: The Life and The Revolution That Changed America") about the "National Review" founder and "Firing Line" TV debater who drew acclaim and criticism, and how the celebrity intellectual paved the way for President Donald Trump. READ AN EXCERPT: "Buckley: The Life and the Revolution That Changed America" For more info: "Buckley: The Life and the Revolution That Changed America" by Sam Tanenhaus (Random House), in Hardcover, eBook and Audio formats, available via Amazon, Barnes & Noble and Gingrich on Instagram NATURE: Glacier National Park in Montana WEB EXCLUSIVES: FROM THE ARCHIVES: Bill Moyers on rebuilding a South Carolina church (Video)Acclaimed TV journalist Bill Moyers died on Thursday, June 26, 2025 at age 91. In this story that aired on "CBS Sunday Morning" on Nov. 3, 1985, Moyers reported on the desecration, by racist vandals, of a small Baptist church in Dixiana, South Carolina, and about how Black and White members of the community joined together with "willing hands and hearts" to restore what had been a fixture of the town since 1857. FROM THE ARCHIVES: OceanGate Titan sub tragedy (YouTube Video)"CBS Sunday Morning" correspondent David Pogue spoke with OceanGate CEO Stockton Rush in 2022 about the company's submersible built for tours to see the wreckage of the Titanic. Rush and four others died in June 2023 after the vessel imploded during a dive in the Atlantic Ocean. Here's a look at our coverage of the submersible, including behind-the-scenes footage with Rush. FROM THE ARCHIVES: The Great American Solar Eclipse (Video)NASA astrophysicist Fred Espenak (also known as "Mr. Eclipse") died on June 1, 2025. In this 2017 "Sunday Morning" report, the "umbraphile" (or lover of shadows) talked with correspondent Martha Teichner about the astronomical awe engendered by eclipses. MARATHON: Going off the grid and finding peace (YouTube Video)Join "CBS Sunday Morning" as they disconnect from technology, look back on retiring electronics and explore an unhooked rotary: Jim Gaffigan on lessons of an uncharged phoneTuscan town without cellphonesCell phone inventor on his first public callLast call for the phone boothiPhone's 10th birthdayGoodbye to the BlackberryMaking calls to lost family The Emmy Award-winning "CBS News Sunday Morning" is broadcast on CBS Sundays beginning at 9:00 a.m. ET. Executive producer is Rand Morrison. DVR Alert! Find out when "Sunday Morning" airs in your city "Sunday Morning" also streams on the CBS News app beginning at 11:00 a.m. ET. (Download it here.) Full episodes of "Sunday Morning" are now available to watch on demand on and Paramount+, including via Apple TV, Android TV, Roku, Chromecast, Amazon FireTV/FireTV stick and Xbox. Follow us on Twitter/X; Facebook; Instagram; YouTube; TikTok; Bluesky; and at You can also download the free "Sunday Morning" audio podcast at iTunes and at Now you'll never miss the trumpet! Breaking down major Supreme Court ruling on nationwide injunctions Jeff Bezos and Lauren Sánchez set for star-studded wedding in Venice Last living WWII Army Rangers awarded Congressional Gold Medal

Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize
Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize

Yahoo

time23 minutes ago

  • Yahoo

Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize

Jennifer Lynn-Pullman is a certified specialist in obesity and weight management, so she was frustrated when her own weight kept rising over the years. 'I had struggled with my weight for a long time. My whole family struggles as well, so it's very genetic,' Lynn-Pullman, 48, a registered dietitian and manager of clinical dietetics for Vida Health, tells "And of course, in your 40s with perimenopause, it doesn't get any easier.' Lynn-Pullman, who lives in suburban Philadelphia, was alarmed when her cholesterol went up for the first time two years ago and her A1C — a measure of blood sugar — was trending up. At 5 feet, 6 inches tall, she weighed 200 pounds and worried she was on track to develop Type 2 diabetes in her 50s like her parents. Her doctor prescribed Wegovy, the version of Ozempic approved for weight loss. It's part of the GLP-1 class of medications that mimic a hormone the body produces after eating to decrease appetite and help the body manage insulin production. After starting the drug in 2023, Lynn-Pullman lost 60 pounds in 10 months and has maintained that weight for more than a year. Like many patients, she experienced side effects and had to figure out which foods to avoid on a GLP-1 and how to prevent muscle loss. Here are her tips for eating on a GLP-1 based on her own experience: Lynn-Pullman had side effects for the first six months, usually when her medication dosage was increased. GLP-1 drugs slow stomach emptying, one of the reasons patients can experience uncomfortable symptoms. Nausea and vomiting are some of the most common side effects. For nausea, Lynn-Pullman prefers to use ginger gum. She also prepares easy to digest foods like a smoothie, soup and crackers that aren't too heavy for her stomach. Vomiting is usually due to eating too much or consuming high-fat foods, so she advises eating smaller meals, not eating too fast and avoiding greasy foods. 'Fat just stays in your stomach longer,' she says. 'With someone whose stomach is emptying much slower, it causes more of an upset.' Lynn-Pullman realized her vomiting episodes were caused by high-fiber muffins she was eating to help ease constipation. Once she cut them out, the problem stopped. The dietitian decided to treat herself like her bariatric surgery patients. 'I realized that because Wegovy causes such an increased level of satiety and such a long level of fullness, that it was very similar to those patients,' she says. Lynn-Pullman eats very small frequent meals she sometimes calls 'eating episodes.' She eats a higher-protein diet to help combat any muscle loss. She has protein every time she eats, consuming that food first, then fruits and vegetables. Any starchy food is last, if there's even room for it. Since liquid fills up the stomach, she suggests not drinking beverages with meals to get enough food in, then hydrating between meals. Here's her typical daily menu: Breakfast: A protein shake, cereal with fiber and ultrafiltered milk, which contains more protein than regular milk. Lunch: A turkey sandwich or salad topped with chicken. Dinner: Chicken or salmon with a vegetable. She occasionally eats rice or pasta on the side, but it fills her up too much, so she usually skips it. Snacks: An apple with peanut butter or nuts with a piece of fruit. Lynn-Pullman always loved sweets, noting she couldn't pass up a cookie or a piece of chocolate, especially in the afternoon. But after she began using Wegovy, she stopped craving sugar. 'It was the most miraculous thing,' Lynn-Pullman recalls. 'The food noise, that inner voice saying, 'Go get something sweet' — it vanished.' Today, she occasionally eats dark chocolate or might split a dessert with her husband if she goes out to dinner, but mostly skips sweets. When it comes to alcohol, she has a drink 'once in a blue moon if she goes to a party." 'The thing that I worry about is being nauseous or even feeling dehydrated the next day,' Lynn-Pullman says. 'We usually suggest that patients refrain from it just because of all of those potential side effects.' The dietitian works out three times a week, focusing on weight training to minimize muscle loss. Three months after starting Wegovy, Lynn-Pullman noticed she was cold all the time, even in the August summer heat. She began journaling her food intake and discovered she was eating only 800 calories a day, with very little protein. 'It's easy to do on a GLP-1 because you don't feel hungry and you fill up quickly,' Lynn-Pullman says. 'We worry about malnutrition, we worry about people not getting enough nutrients.' When she started eating more protein and calories, her symptoms went away quickly. That's why it's important to work with a dietitian and report symptoms like feeling cold, tired or exhausted, or noticing hair loss — potential symptoms of eating too little, Lynn-Pullman notes. This article was originally published on

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Yahoo

time33 minutes ago

  • Yahoo

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store